By 2030, it is anticipated that the Indonesia HIV therapeutics market will reach a value of $xx Mn from $82.6 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as PT Dexa Medica, PT Sanbe Farma, and PT Kimia Farma Tbk. The market for HIV/AIDS treatment in Indonesia is primarily driven by government funding and initiatives, social issues like stigma and discrimination, and diagnostic tools. The HIV therapeutics market in Indonesia is segmented by type, product, geography, end user, and distribution channel.
By 2030, it is anticipated that the Indonesia HIV therapeutics market will reach a value of $xx Mn from $82.6 Mn in 2022, growing at a CAGR of xx% during 2022-2030.
In Indonesia, there were 569,903 HIV/AIDS cases overall as of June 2021, including 436,948 HIV cases and 132,955 AIDS cases. In honor of World AIDS Day 2017, the Indonesian government unveiled a new HIV test and treatment policy. Anyone with HIV should start antiretroviral therapy as soon as possible after being diagnosed.
In 2018, Indonesia spent $119 Mn on AIDS, with 71% of that coming from domestic sources and 29% from foreign sources. The Indonesian government has stepped up initiatives to offer free ART and enhance the nation's healthcare system. Along with promoting the development of fresh and cutting-edge approaches to HIV/AIDS care, NGOs and international organizations are also working to raise awareness and lessen stigma. In Indonesia, the general government spends $175.33 on healthcare per person.
Market Growth Drivers Analysis
In 2020, the national HIV prevalence among adults 15 and older is predicted to be 0.26 percent. The HIV epidemic in Indonesia, with the exception of the Papua provinces, is concentrated among certain key populations. In 2018, APBD (the local budget) provided $580,000 to DKI Jakarta (Indonesia) for HIV-related services.
Market Restraints
There is a lack of knowledge and a low willingness to seek treatment. Only 17% of Indonesia's pregnant HIV-positive women have received antiretroviral medication in 2020, preventing transmission from mother to child.
Key Players
The Ministry of Health of the Republic of Indonesia and the Indonesia National Agency of Drug and Food Control are the regulatory bodies specifically responsible for overseeing drugs, biologicals, and medical devices in Indonesia.
The Social Security Management Board (Badan Penyelenggara Jaminan Sosial, or "BPJS") includes the health BPJS, which oversees the health security program. The health BPJS will receive contribution aid from the Indonesian Government as an additional source of funding for the purpose of sponsoring the underprivileged and impoverished so that they can be covered by the health security program. According to the rules of the health security program, the health BPJS will pay for the participants' medical expenses.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Types (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.